ストックスクリーナーアプリを入手
3.76
3.87%
0.14
前日終値:
$3.62
開ける：
$3.64
24時間の取引高:
4.16M
Relative Volume:
4.16
時価総額：
$254.60M
収益：
$6.96M
当期純損益:
$-46.51M
株価収益率:
-21.91
EPS:
-0.1716
ネットキャッシュフロー:
$-37.99M
1週間 パフォーマンス:
+8.67%
1か月 パフォーマンス:
+56.67%
6か月 パフォーマンス:
+17.87%
1年 パフォーマンス:
-61.90%
1日の値動き範囲:
$3.4698
$3.86
1週間の範囲:
$3.37
$4.44
52週間の値動き範囲:
$1.60
$16.55
Perspective Therapeutics Inc Stock (CATX) Company Profile
名前
Perspective Therapeutics Inc
セクター
電話
509-375-1202
住所
350 Hills Street, Suite 106, Richland
CATX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.76 | 254.60M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
134.38 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.53 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
393.55 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.02 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.21 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-11-25 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-01 | 開始されました | Wedbush | Outperform |
| 2024-09-25 | 開始されました | Truist | Buy |
| 2024-07-25 | 開始されました | BofA Securities | Buy |
| 2024-05-09 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Perspective Therapeutics Inc (CATX) 最新ニュース
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of “Buy” from Analysts - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Bank of America Corp DE - Defense World
Analyzing Ratios: Perspective Therapeutics Inc (CATX)’s Financial Story Unveiled - DWinneX
The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic - insights.citeline.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Cantor Fitzgerald Forecasts CATX FY2026 Earnings - Defense World
Ameriprise Financial Inc. Sells 645,170 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
151,610 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Acquired by Two Sigma Advisers LP - Defense World
ProShare Advisors LLC Acquires 5,011 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics (NYSE:CATX) Rating Increased to Moderate Buy at Royal Bank of Canada - Defense World
Perspective Therapeutics (CATX) Price Target Raised by RBC Capital | CATX Stock News - GuruFocus
Perspective Therapeutics (CATX) Gets a Buy from Scotiabank - The Globe and Mail
RBC Capital Boosts Price Target for Perspective Therapeutics (CA - GuruFocus
Perspective Therapeutics Updates on Radiopharmaceutical Advancements - TipRanks
RBC Capital raises Perspective Therapeutics stock price target to $16 By Investing.com - Investing.com Nigeria
RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk - marketscreener.com
RBC Capital raises Perspective Therapeutics stock price target to $16 - Investing.com
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Nuveen Asset Management LLC - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Deutsche Bank AG - Defense World
Two Sigma Investments LP Takes $2.08 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (CATX) Reports Positive Results for NET Treatment Trial - Insider Monkey
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-?-NET at the 2025 ASCO Annual Meeting | CATX Stock News - GuruFocus
Perspective Therapeutics Provides Updated Interim Results and Safety Findings for [212Pb]VMT-α-NET at ASCO 2025 - Nasdaq
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting - The Manila Times
Millennium Management LLC Buys New Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Neuroendocrine Tumors Market: Epidemiology, Therapies, - openPR.com
Perspective Therapeutics Announces Voting Results By Investing.com - Investing.com Canada
Perspective Therapeutics Holds Annual Stockholders Meeting - TipRanks
Perspective Therapeutics Announces Voting Results - Investing.com
Northern Trust Corp Acquires 13,115 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Janus Henderson Group PLC Has $57,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Brokerages - Defense World
HC Wainwright Has Pessimistic Outlook of CATX Q3 Earnings - Defense World
Equities Analysts Offer Predictions for CATX Q1 Earnings - Defense World
Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential - MSN
Head-To-Head Review: Avinger (NASDAQ:AVGR) and Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics’ SWOT analysis: rare disease stock faces clinical hurdles - Investing.com Nigeria
Mercer Global Advisors Inc. ADV Invests $51,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics Reports Q1 2025 Earnings - TipRanks
Perspective Therapeutics (CATX) Rating Maintained, Price Target Lowered | CATX Stock News - GuruFocus
Truist Securities Adjusts Perspective Therapeutics Price Target to $8 From $10, Maintains Buy Rating - marketscreener.com
Oppenheimer cuts CATX stock price target to $15, maintains Outperform By Investing.com - Investing.com South Africa
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results | CATX Stock News - GuruFocus
Oppenheimer Trims Perspective Therapeutics Price Target to $15 From $16, Maintains Outperform Rating - marketscreener.com
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Wells Fargo & Company MN - Defense World
Oppenheimer cuts CATX stock price target to $15, maintains Outperform - Investing.com
Perspective Therapeutics: Q1 Earnings Snapshot - The Washington Post
Perspective Therapeutics Inc (CATX) Q1 2025 Earnings: EPS Loss of $0.25 Beats Estimate, Revenue of $0.3M Exceeds Expectations - GuruFocus
Perspective Therapeutics Reports Q1 2025 Results and Updates - TipRanks
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results - The Manila Times
Perspective Therapeutics, Inc. Announces Clinical Updates and Recruitment Progress for Novel Radiopharmaceuticals Ahead of 2025 ASCO Meeting - Nasdaq
Perspective Therapeutics Inc (CATX) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
0.64%
大文字化:
|
ボリューム (24 時間):